

Anti-CD3/DLL3 Antibody (Taratamab)

Introduction

Taratamab is a novel bispecific T cell engaging antibody (BiTE) developed by Amgen. It consists of two single-chain variable fragments (scFv), one targeting the CD3 molecule and the other targeting the DLL3 molecule. Taratamab activates T cells and kills tumor cells by directing them to tumor cells expressing DLL3, and is mainly used to treat small cell lung cancer (SCLC).

Product parameters

Alternative Names	AMG 757
Target Accession	-
Target	CD3/DLL3
CAS number	2307488-83-9
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

